Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial

Objectives Tanezumab, a monoclonal antibody, inhibits nerve growth factor and reduces chronic pain. This randomised, double-blind, controlled multicentre study was conducted to evaluate the efficacy and safety of tanezumab added to oral diclofenac sustained release (DSR) in patients with hip or knee...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of the rheumatic diseases 2014-09, Vol.73 (9), p.1665-1672
Hauptverfasser:	Balanescu, Andra Rodica, Feist, Eugen, Wolfram, Gernot, Davignon, Isabelle, Smith, Michael D, Brown, Mark T, West, Christine R
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Analgesics Anti-Inflammatory Agents, Non-Steroidal - administration & dosage Anti-Inflammatory Agents, Non-Steroidal - adverse effects Anti-Inflammatory Agents, Non-Steroidal - therapeutic use Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Arthritis Clinical trials Committees Delayed-Action Preparations Diclofenac - adverse effects Diclofenac - therapeutic use Dose-Response Relationship, Drug Double-Blind Method Drug Therapy, Combination Female Humans Immunoglobulins Male Middle Aged Osteoarthritis, Hip - complications Osteoarthritis, Hip - drug therapy Osteoarthritis, Knee - complications Osteoarthritis, Knee - drug therapy Pain - etiology Pain - prevention & control Pain management Pain Measurement - methods Patient safety Receptor, Nerve Growth Factor - antagonists & inhibitors Rheumatology Severity of Illness Index Signal transduction Studies Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!